: Axsome’s stock falls after disclosing Teva’s plans to market generic Auvelity


Shares of Axsome Therapeutics Inc. AXSM, -0.27% tumbled about 10.0% in premarket trading on Monday after the company said in a securities filing that Teva Pharmaceutical Industries Ltd. TEVA, +4.48% is seeking approval from the Food and Drug Administration to market a generic version of Auvelity, Axsome’s depression treatment. Axsome’s stock has gained 95.8% over the past year, while the S&P 500 SPX, +0.22% declined 7.6%.

Item 8.01 Other Events.

This article was originally published by Marketwatch.com. Read the original article here.

Previous articleBond Report: U.S. Treasury yields hold near six-week highs as inflation data looms
Next articleMetals Stocks: Gold prices retreat as investors await Tuesday’s U.S. inflation report


Please enter your comment!
Please enter your name here